AbbVie says Qulipta hit Phase 3 goal for menstrual migraine
AbbVie said Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine. The trial tested a sharper, more targeted treatment schedule, with results cited by the company as meeting the main goal.